QUICK ANSWER · AEO / GEO
Ligandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- Short biomarker/body-composition trial ≠ clinical benefit ≠ long-term safety; LGD-4033 label ≠ verified compound
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Ligandrol / LGD-4033?
Ligandrol / LGD-4033 is described pharmacologically as Nonsteroidal selective androgen receptor modulator candidate. Ligandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times.
Does Ligandrol / LGD-4033 have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Ligandrol / LGD-4033 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.